Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. (Q39874679)
Jump to navigation
Jump to search
scientific article published on 10 March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. |
scientific article published on 10 March 2009 |
Statements
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression (English)
Klaus P Hoeflich
Sylvia Herter
Janet Tien
Leo Wong
Leanne Berry
Jocelyn Chan
Carol O'Brien
Somasekar Seshagiri
Howard Stern
Edna Choo
Lesley Murray
Lori S Friedman
Marcia Belvin
10 March 2009
1 reference